April 2011
Volume 52, Issue 14
Free
ARVO Annual Meeting Abstract  |   April 2011
A Strategy To Induce Corneal Endothelial Cell Replication Using A Reverse Transcription Defective Lentiviral Vector
Author Affiliations & Notes
  • Mark Basche
    Genetics, UCL Institute of Ophthalmology, London, United Kingdom
  • Daniel Kampik
    Genetics, UCL Institute of Ophthalmology, London, United Kingdom
  • Alexander Smith
    Genetics, UCL Institute of Ophthalmology, London, United Kingdom
  • Frank Larkin
    Moorfields Eye Hospital, London, United Kingdom
  • Robin Ali
    Genetics, UCL Institute of Ophthalmology, London, United Kingdom
  • Footnotes
    Commercial Relationships  Mark Basche, None; Daniel Kampik, None; Alexander Smith, None; Frank Larkin, None; Robin Ali, None
  • Footnotes
    Support  Fight for Sight, Moorfields Eye Hospital and UCL Institute of Ophthalmology BMRC for Ophthalmology
Investigative Ophthalmology & Visual Science April 2011, Vol.52, 6461. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Mark Basche, Daniel Kampik, Alexander Smith, Frank Larkin, Robin Ali; A Strategy To Induce Corneal Endothelial Cell Replication Using A Reverse Transcription Defective Lentiviral Vector. Invest. Ophthalmol. Vis. Sci. 2011;52(14):6461.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: : The osmotic activity of corneal endothelial cells (CECs) maintains the clarity of the eye’s cornea. CECs are non-replicative in humans and any decrease of their density due to aging, injury, surgical trauma etc can lead to corneal swelling and a loss of transparency. Thus transduction of CECs with an oncogene such as YAP1, which has described roles regulating cell cycle progression and contact inhibition, could be a potential therapy. However, such gene transfer carries substantial risks. We investigate whether modifications to the lentiviral lifecycle could improve the safety profile of gene delivery by mediating a low-level, temporary gene expression. Additionally we characterised the endogenous expression pattern of YAP1 in the CECs as a candidate therapeutic gene.

Methods: : We modified our Lentiviral vectors by deleting the tRNA Primer Binding Site (dPBS) from the genome thus rendering the vectors incapable of undergoing reverse transcription. No promoter was necessary in these constructs. Proof of concept was carried out using a vector encoding Luciferase (dPBS-LUC2) with a PBS intact SFFV-LUC2 vector serving as the control. Luciferase expression was quantified using Promega’s Bright-Glo reagents and a BMG Labtech Luminometer. Human corneal tissue with a normal endothelium was obtained from the eye bank and maintained in ex-vivo culture. Endogenous YAP1 expression in the endothelium was investigated by immunohistochemistry.

Results: : Transduction of HEK293T cells with dPBS-LUC2 resulted in detectable amounts of LUC2 ~2-logs above background maintained for >70 hours. Transduction compared to control was >4-logs reduced. The expression of YAP1 in CECs is almost exclusively confined to the cytoplasm; a pattern consistent with a strongly contact inhibited tissue.

Conclusions: : Lentiviral vectors carrying the dPBS mutation are capable of delivering quantifiable amounts of protein to cells. Genes carried by such vectors should never be encoded as DNA and thus integration and sustained expression are highly unlikely. Nuclear overexpression of YAP1 in CECs could provide a means to break their contact inhibition and initiate cell replication.

Keywords: cornea: endothelium • gene transfer/gene therapy 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×